These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

554 related articles for article (PubMed ID: 37516849)

  • 1. Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategies.
    Muhammad S; Fan T; Hai Y; Gao Y; He J
    Mol Cancer; 2023 Jul; 22(1):121. PubMed ID: 37516849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.
    Lopes JE; Fisher JL; Flick HL; Wang C; Sun L; Ernstoff MS; Alvarez JC; Losey HC
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unveiling the multifaceted antitumor effects of interleukin 33.
    Arrizabalaga L; Risson A; Ezcurra-Hualde M; Aranda F; Berraondo P
    Front Immunol; 2024; 15():1425282. PubMed ID: 38881897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose IL-2/CD25 fusion protein amplifies vaccine-induced CD4
    Hernandez R; LaPorte KM; Hsiung S; Santos Savio A; Malek TR
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34475132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-2 therapy of cancer-clinical perspectives.
    Majidpoor J; Mortezaee K
    Int Immunopharmacol; 2021 Sep; 98():107836. PubMed ID: 34218217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biology of the interleukin-2 receptor.
    Nelson BH; Willerford DM
    Adv Immunol; 1998; 70():1-81. PubMed ID: 9755337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of IL-2 and IL-2R SNPs on proliferation and tumor- killing activity of lymphokine-activated killer cells from healthy chinese blood donors.
    Li Y; Meng FD; Tian X; Sui CG; Liu YP; Jiang YH
    Asian Pac J Cancer Prev; 2014; 15(18):7965-70. PubMed ID: 25292096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining the Threshold IL-2 Signal Required for Induction of Selective Treg Cell Responses Using Engineered IL-2 Muteins.
    Ghelani A; Bates D; Conner K; Wu MZ; Lu J; Hu YL; Li CM; Chaudhry A; Sohn SJ
    Front Immunol; 2020; 11():1106. PubMed ID: 32582190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy.
    Maccalli C; Parmiani G; Ferrone S
    Immunol Invest; 2017 Apr; 46(3):221-238. PubMed ID: 28287848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The circadian rhythm key gene
    Wu G; Ren H; Hu Q; Ma H; Chen H; Zhou L; Xu K; Ding L
    Front Immunol; 2023; 14():1115809. PubMed ID: 37275880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic gene modified cell based cancer vaccines.
    Kozłowska A; Mackiewicz J; Mackiewicz A
    Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune checkpoint targeting antibodies hold promise for combinatorial cancer therapeutics.
    Ritu ; Chandra P; Das A
    Clin Exp Med; 2023 Dec; 23(8):4297-4322. PubMed ID: 37804358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel role of metalloproteinase in cancer-mediated immunosuppression.
    Sheu BC; Hsu SM; Ho HN; Lien HC; Huang SC; Lin RH
    Cancer Res; 2001 Jan; 61(1):237-42. PubMed ID: 11196168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deep immunophenotyping at the single-cell level identifies a combination of anti-IL-17 and checkpoint blockade as an effective treatment in a preclinical model of data-guided personalized immunotherapy.
    Nagaoka K; Shirai M; Taniguchi K; Hosoi A; Sun C; Kobayashi Y; Maejima K; Fujita M; Nakagawa H; Nomura S; Kakimi K
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33093158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained IL-2R signaling of limited duration by high-dose mIL-2/mCD25 fusion protein amplifies tumor-reactive CD8
    Hernandez R; Toomer KH; Põder J; Santos Savio A; Hsiung S; Malek TR
    Cancer Immunol Immunother; 2021 Apr; 70(4):909-921. PubMed ID: 33037893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rethinking Oncologic Treatment Strategies with Interleukin-2.
    Ko B; Takebe N; Andrews O; Makena MR; Chen AP
    Cells; 2023 May; 12(9):. PubMed ID: 37174716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual anti-OX40/IL-2 therapy augments tumor immunotherapy via IL-2R-mediated regulation of OX40 expression.
    Redmond WL; Triplett T; Floyd K; Weinberg AD
    PLoS One; 2012; 7(4):e34467. PubMed ID: 22496812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Which immunological parameters are clinically essential to monitor IL-2 cancer immunotherapy?
    Lissoni P; Brivio F; Viviani S; Fumagalli L
    J Biol Regul Homeost Agents; 1999; 13(2):110-4. PubMed ID: 10503734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Independent expression of p55 and p75 interleukin-2 receptors (IL-2R) during intravenous or subcutaneous administration of recombinant interleukin-2 (rIL-2) by T-lymphocytes and natural killer cells.
    Zambello R; Trentin L; Cerutti A; Enthammer C; Milani A; Franceschi T; Messina C; Cetto GL; Agostini C; Semenzato G
    Cancer; 1994 Nov; 74(9):2562-9. PubMed ID: 7522954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate Cancer Immunotherapy-Finally in From the Cold?
    Runcie KD; Dallos MC
    Curr Oncol Rep; 2021 Jun; 23(8):88. PubMed ID: 34125308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.